See more : CBOA Financial, Inc. (CBOF) Income Statement Analysis – Financial Results
Complete financial analysis of INmune Bio, Inc. (INMB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of INmune Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ProtoSource Corporation (PSCO) Income Statement Analysis – Financial Results
- TMK Energy Limited (TMK.AX) Income Statement Analysis – Financial Results
- Canadian Palladium Resources Inc. (BULL.CN) Income Statement Analysis – Financial Results
- Cardinal Energy Ltd. (CJ.TO) Income Statement Analysis – Financial Results
- COSCO SHIPPING Holdings Co., Ltd. (1919.HK) Income Statement Analysis – Financial Results
INmune Bio, Inc. (INMB)
About INmune Bio, Inc.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 155.00K | 374.00K | 181.00K | 10.92K | 77.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 155.00K | 374.00K | 181.00K | 10.92K | 77.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.27M | 17.07M | 20.54M | 5.92M | 3.28M | 1.11M | 435.36K | 101.50K | 0.00 |
| General & Administrative | 9.62M | 9.26M | 8.79M | 6.32M | 6.02M | 11.33M | 546.12K | 126.00K | 195.47K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -146.60K |
| SG&A | 9.62M | 9.26M | 8.79M | 6.32M | 6.02M | 11.33M | 546.12K | 126.00K | 48.87K |
| Other Expenses | 0.00 | -1.35M | -1.19M | 128.52K | 0.00 | 0.00 | -6.00 | 0.00 | 0.00 |
| Operating Expenses | 29.90M | 26.33M | 29.33M | 12.24M | 9.30M | 12.44M | 981.48K | 227.49K | 48.87K |
| Cost & Expenses | 29.90M | 26.33M | 29.33M | 12.24M | 9.30M | 12.44M | 981.48K | 227.49K | 48.87K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 77.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.74M | 25.95M | 29.15M | 12.23M | 9.30M | 12.44M | 981.48K | 227.49K | 195.47K |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 149.99K | -50.00K | 146.60K |
| EBITDA Ratio | 0.00% | -6,938.77% | -16,106.63% | -112,016.09% | -13.95% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.74M | -25.95M | -29.15M | -12.23M | -7.76M | -12.44M | -981.48K | -227.49K | -48.87K |
| Operating Income Ratio | -19,187.74% | -6,938.77% | -16,106.63% | -112,016.09% | -9.98% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -267.00K | -1.35M | -1.19M | 129.00K | 77.69K | 0.00 | 149.99K | -50.00K | 0.00 |
| Income Before Tax | -30.01M | -27.30M | -30.34M | -12.10M | -7.68M | -12.44M | -831.49K | -277.49K | -48.87K |
| Income Before Tax Ratio | -19,360.00% | -7,299.20% | -16,762.43% | -110,838.76% | -9.88% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.35M | -29.15M | -12.23M | 1.46M | -161.14K | -1.13M | -177.49K | 0.00 |
| Net Income | -30.01M | -28.65M | -30.34M | -12.10M | -9.14M | -12.44M | -831.49K | -277.49K | -48.87K |
| Net Income Ratio | -19,360.00% | -7,659.63% | -16,762.43% | -110,838.76% | -11.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.67 | -1.60 | -1.88 | -1.01 | -0.89 | -1.11 | -0.07 | -0.02 | 0.00 |
| EPS Diluted | -1.67 | -1.60 | -1.88 | -1.01 | -0.89 | -1.11 | -0.07 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 11.22M | 11.22M | 11.22M | 11.22M |
| Weighted Avg Shares Out (Dil) | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 11.22M | 11.22M | 11.22M | 11.22M |
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
An in-depth analysis of MRI gray matter microstructure following treatment with XPro™ shows that the greatest improvement was in the earliest and most affected regions of the AD brain; an effect that was accompanied by an improvement in neuronal proteins...
INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 16, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that...
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient's immune system to fight disease, announced today that RJ Tesi, MD, Chief Executive Officer, and...
INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer's Disease
The authorization provides approval for the Company to expand the ongoing Phase 2 trial of XPro ™ in patients with early Alzheimer's disease to the U.K.
INmune Bio, Inc. (INMB) Q2 2023 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer & Chief Medical Officer Conference Call Participants Joel Beatty -...
INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update
BOCA RATON, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for...
INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
Boca Raton, FL, Aug. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient's immune system to fight disease, announced today that RJ Tesi, MD, CEO and David Moss,...
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a...
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies to Improve Health Span by Treating the Chronic Diseases of Aging
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer's Disease
Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM
Source: https://incomestatements.info
Category: Stock Reports